New strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28055

Enrollment

396

Registered

2019-09-10

Start date

2018-12-13

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: criteria: - Adult: o Group 1: germline mutation RB1. o Group 2 (control): no germline mutation RB1. - Pediatric: o Group 1: somatic or germline mutation RB1 o Group 2 (control): no mutation RB1.

Exclusion criteria

Exclusion criteria: - Adult: o Group 1: concomitant heritable (inherited) disorder other than caused by monoalleic mutation of RB1. o Group 2 (control): cancer or already known cancer predisposition syndrome. - Pediatric: o Group 1: concomitant heritable (inherited) disorder other than caused by monoalleic mutation of RB1. o Group 2: cancer or already known cancer predisposition syndrome.

Design outcomes

Primary

Measure	Time frame
1. Determine the non-cancerous baseline in adult RB1-mutation carriers (Rb-survivors). 2. Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers with SPMs.	—

Contacts

Public ContactArmida Fabius

Amsterdam UMC

a.fabius@amsterdamumc.nl+31204440285

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)